Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

JACC. Advances·2026

Same author

Hickam's Dictum in Hypertension.

Hypertension (Dallas, Tex. : 1979)·2025

Same author

Managing Hypertension in Older Adults.

Current hypertension reports·2023

Same author

How We Got Where We Are in Blood Pressure Targets.

Current hypertension reports·2021

Same author

Uncontrolled Hypertension in an Elderly Man on Multiple Antihypertensive Drugs.

Hypertension (Dallas, Tex. : 1979)·2020

Same author

Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association.

Circulation·2020

Search research articles

Related Experiment Videos

Beta-blockers for preventing sudden cardiac death.

Thomas D Giles¹, Jan N Basile

¹Division of Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA. tgiles@lsuhsc.edu

Postgraduate Medicine

|August 12, 2009

Summary

Beta-blockers are crucial for preventing sudden cardiac death, a major cause of mortality from heart disease. Clinical trials confirm their role in reducing ventricular arrhythmias and improving patient survival rates.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology

Background:

Sudden cardiac death (SCD) accounts for approximately 300,000 US deaths annually, representing half of all coronary heart disease fatalities.
Ventricular arrhythmias are a primary cause of SCD.

Purpose of the Study:

To review the established role of beta-blockade in preventing sudden cardiac death.
To highlight clinical evidence supporting beta-blocker use for improved survival.

Main Methods:

Review of numerous randomized, controlled trials on beta-blocker efficacy.
Analysis of clinical evidence associating beta-blockade with survival outcomes.

Main Results:

Beta-blockers were the first drug class investigated for preventing sudden cardiac arrest.
Numerous trials have confirmed the importance of beta-blockade in preventing SCD.
Clinical evidence demonstrates an association between beta-blockade and improved survival.

Conclusions:

Beta-blockade is a vital therapeutic strategy for the prevention of sudden cardiac death.
Ongoing trials continue to explore and confirm the role of beta-blockers in reducing cardiac mortality.